Scarica l'app Stockscreener
17.81
7.29%
1.21
Dopo l'orario di chiusura:
17.98
0.17
+0.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Precedente Chiudi:
$16.60
Aprire:
$16.41
Volume 24 ore:
5.27M
Relative Volume:
0.85
Capitalizzazione di mercato:
$5.54B
Reddito:
-
Utile/perdita netta:
$-124.55M
Rapporto P/E:
-40.54
EPS:
-0.4393
Flusso di cassa netto:
$-95.58M
1 W Prestazione:
+17.48%
1M Prestazione:
+22.57%
6M Prestazione:
+736.15%
1 anno Prestazione:
+1,313%
Intervallo 1D:
$16.29
$18.18
Intervallo di 1 settimana:
$14.54
$18.18
Portata 52W:
$1.01
$18.18
Erasca Inc Stock (ERAS) Company Profile
Nome
Erasca Inc
Settore
Industria
Telefono
(858) 465-6511
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
17.81 | 5.54B | 0 | -124.55M | -95.58M | -0.4393 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Ripresa | Mizuho | Outperform |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | Jefferies | Buy |
| 2024-03-11 | Iniziato | CapitalOne | Overweight |
| 2024-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-30 | Iniziato | Mizuho | Buy |
| 2023-02-24 | Iniziato | Goldman | Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Erasca Inc Borsa (ERAS) Ultime notizie
JPMorgan and Stifel Enhance Erasca’s Market Prospects with High Price Targets - timothysykes.com
Erasca CLO Ebun Garner sells $1.3m in ERAS stock By Investing.com - Investing.com Australia
Insider Selling: Erasca (NASDAQ:ERAS) Insider Sells 80,000 Shares of Stock - marketbeat.com
Erasca CLO Ebun Garner sells $1.3m in ERAS stock - Investing.com
Erasca (ERAS) Chief Legal Officer exercises options, sells 80K shares under 10b5-1 plan - Stock Titan
Erasca (NASDAQ:ERAS) Trading 8.2% HigherHere's What Happened - MarketBeat
Erasca Inc stock hits 52-week high at $14.63 - Investing.com
Erasca reports proposed 80,000-share sale (NASDAQ: ERAS) - Stock Titan
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Erasca Inc stock hits 52-week high at 16.41 USD - Investing.com
Erasca Inc stock hits 52-week high at 16.41 USD By Investing.com - Investing.com India
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN
ERAS Technical Analysis & Stock Price Forecast - Intellectia AI
Revenue Check: How does Erasca Inc perform in inflationary periods2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Erasca (ERAS) price target increased by 42.72% to 14.99 - MSN
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't - Yahoo Finance
Erasca (NASDAQ:ERAS) Shares Up 8.8%Should You Buy? - MarketBeat
Erasca’s Stock Surges Higher Amid Pipeline Optimism - StocksToTrade
Erasca’s HERKULES-3 Trial Reaches Completion: What Investors Should Watch in ERAS-007 - TipRanks
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Erasca (ERAS) adds 13%; soars 310% YTD - MSN
Mizuho initiates Erasca (ERAS) with 'outperform' rating and $16 PT - msn.com
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation - Yahoo Finance
Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - MarketScreener
A Look At Erasca (ERAS) Valuation After Its Strong Recent Share Price Rally - simplywall.st
How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors - simplywall.st
Erasca (ERAS) Adds 13%; Soars 310% YTD - Insider Monkey
5 Stocks Dominating Today’s Market Action - Insider Monkey
Erasca (NASDAQ:ERAS) Shares Up 10.3% on Better-Than-Expected Earnings - MarketBeat
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
ERAS Surges as JP Morgan Raises Price Target | ERAS Stock News - GuruFocus
JPMorgan Chase & Co. Increases Erasca (NASDAQ:ERAS) Price Target to $25.00 - MarketBeat
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Chipmakers Recap: Should I invest in Erasca Inc before earnings2026 Valuation Update & Weekly Sector Rotation Insights - baoquankhu1.vn
Erasca Form 144: Foundation Lists Proposed Common Sales | ERAS SEC FilingForm 144 - Stock Titan
Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Erasca’s Stock Faces Pressure as CMO Offloads Shares - StocksToTrade
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - AOL.com
Erasca’s CMO Stock Sale Raises Eyebrows Amid Market Uncertainty - timothysykes.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com - Investing.com Nigeria
Erasca Inc Azioni (ERAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Erasca Inc Azioni (ERAS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Garner Ebun | Chief Legal Officer |
Apr 01 '26 |
Sale |
16.40 |
80,000 |
1,312,000 |
25,076 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):